Possible Base Breakout After Upgraded Forecast: Healthcare Company Fresenius Continuing on Recovery Path
Reading Time: 1 minute
The globally active healthcare company Fresenius raised its forecast for organic revenue growth for the full year to 5-7% last week. The main growth drivers were the persistently strong organic growth in the core businesses of Fresenius Kabi and Fresenius Helios. Fresenius Kabi recorded particularly strong developments in the areas of Biopharma (+33% organic), MedTech (+5%), and Pharma (+5%). In the Biopharma segment, new products such as Tyenne (launch in Europe and the USA) and the biosimilars Conexxence® and Bomyntra® (Denosumab) were successfully...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
